PRALUENT® (alirocumab) Patient Types

PRALUENT: An LDL-C lowering option for patients you often see in clinical practice

Scroll through examples of appropriate patients* for PRALUENT

PRALUENT in hypercholesterolemia patients with a history of coronary revascularization
 

 

Hypercholesterolemia with history of coronary revascularization (example of clinical ASCVD)

Medical History

  • Uncontrolled hypercholesterolemia
  • Current smoker (33 pack years)
  • Percutaneous transluminal coronary angioplasty 2 years ago (left anterior descending artery)
  • LDL-C was 130 mg/dL on statin alone
  • BMI=30

Current Treatment Regimen

  • Atorvastatin 40 mg/day (maximum tolerated dose)
    • Previously on pravastatin 80 mg/day, for 1 year
  • Ezetimibe 10 mg/day
  • Prasugrel 10 mg/day
  • Aspirin 162 mg/day
GOAL: Achieve targeted LDL-C reduction

For patients like Larry, PRALUENT provides powerful LDL-C reduction on top of a maximally tolerated statin

83% of patients in the COMBO I Study achieved LDL-C goal (<70 mg/dL) at week 8 and did not require up-titration at week 121

Only 17% of patients needed to be up-titrated at week 12 from 75 mg to 150 mg1

  • At week 12: 45% LDL-C reduction with PRALUENT 75 mg vs +1% with placebo
  • ASCVD population: Overall, 84% had clinical ASCVD

Reference:
1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.

PRALUENT in hypercholesterolemia patients with a history of MI and coronary revascularization
 

 

Hypercholesterolemia with history of MI and coronary revascularization (example of clinical ASCVD)

Medical History

  • Uncontrolled hypercholesterolemia
  • History of myocardial infarction, 3 years ago
    • Percutaneous transluminal coronary angioplasty with drug-eluting stent placed in right coronary artery
  • Hypertension, controlled with medication
  • BMI=29
  • Mean baseline LDL-C: 167 mg/dL

Current Treatment Regimen

  • Atorvastatin 40 mg/day (maximum tolerated dose)
    • Previously on simvastatin 40 mg/day, for 1 year
  • Metoprolol 100 mg/day
  • Lisinopril 20 mg/day
  • Aspirin 162 mg/day
Lipid Profile for hypercholesterolemia patients with a history of MI and coronary revascularization
 

 
GOAL: Achieve targeted LDL-C reduction

For patients like Angela, PRALUENT provides additional LDL-C lowering on top of a maximally tolerated statin dose

83% of patients in the COMBO I Study achieved LDL-C goal (<70 mg/dL) at week 8 and did not require up-titration at week 121

Only 17% of patients needed to be up-titrated at week 12 from 75 mg to 150 mg1

  • At week 12: 45% LDL-C reduction with PRALUENT 75 mg vs +1% with placebo
  • ASCVD population: Overall, 84% had clinical ASCVD

Reference:
1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.

PRALUENT in hypercholesterolemia patients with a unstable angina
 

 

Hypercholesterolemia with unstable angina (example of clinical ASCVD)

Medical History

  • Diagnosed with hypercholesterolemia at age 52
  • Hospitalized for unstable angina 6 months ago
  • Hypertension
  • Family history of CAD
    • Mother suffered first MI at age 50

Current Treatment Regimen

  • Rosuvastatin 20 mg/day (maximally tolerated dose)
    • Previously on atorvastatin 40 mg/day, for 1 year
  • Ezetimibe 10 mg/day
  • Carvedilol 40 mg/day
GOAL: Achieve LDL-C reduction

For patients like Evelyn, Choose the power of PRALUENT

PRALUENT offers 2 doses with 2 levels of efficacy1

Powerful LDL-C reduction on top of maximally tolerated statins as shown in 2 clinical trials that included ASCVD patients1

  • Two Q2W doses of PRALUENT were studied: 75 mg and 150 mg
  • Recommended starting dose: 75 mg once every 2 weeks administered subcutaneously or alternatively 300 mg once every 4 weeks (monthly) for patients who prefer less frequent dosing. The majority of patients achieve sufficient LDL-C reduction with the 75-mg dosage1†
  • In the LONG TERM Study: Patients were started on 150 mg
  • Choose the most appropriate dosing regimen for Evelyn based on your clinical judgment

Reference:
1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.

PRALUENT in hypercholesterolemia patients with a history of TIA/cerebrovascular accident
 

 

Hypercholesterolemia with history of TIA/cerebrovascular accident (example of clinical ASCVD)

Medical History

  • Uncontrolled hypercholesterolemia
  • Cerebrovascular accident 1 year ago
  • History of transient ischemic attack (TIA)
  • Hypertension, controlled with medication
  • Obesity (BMI=36)

Current Treatment Regimen

  • Rosuvastatin 40 mg/day (maximally tolerated dose)
  • Atenolol 100 mg/day
  • Lisinopril 20 mg/day/HCTZ 12.5 mg/day
  • Aspirin 81 mg/day
Lipid Profile for hypercholesterolemia patients with a history of TIA/cerebrovascular accident
 

 
GOAL: Achieve targeted LDL-C reduction

For patients like John, PRALUENT provides additional LDL-C lowering on top of a maximally tolerated statin dose

83% of patients in the COMBO I Study achieved LDL-C goal (<70 mg/dL) at week 8 and did not require up-titration at week 121

Only 17% of patients needed to be up-titrated at week 12 from 75 mg to 150 mg1

  • At week 12: 45% LDL-C reduction with PRALUENT 75 mg vs +1% with placebo
  • ASCVD population: Overall, 84% had clinical ASCVD

Reference:
1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.

PRALUENT in hypercholesterolemia patients with a history of MI
 

 

Hypercholesterolemia with history of MI (example of clinical ASCVD)

Medical History

  • Hypercholesterolemia diagnosed at age 48
  • Presented with NSTEMI 6 months ago
  • Type 2 diabetes mellitus
  • Baseline LDL-C: 180 mg/dL

Current Treatment Regimen

  • Atorvastatin 40 mg/day (maximally tolerated dose)
    • Previously on simvastatin 40 mg/day
  • Ezetimibe 10 mg/day
  • Prasugrel 10 mg/day
  • Aspirin 81 mg/day
  • Sitagliptin + metformin 50 mg/500 mg per day
  • NPH insulin (100 U/mL) 10 units at bedtime
Lipid Profile for hypercholesterolemia patients with a history of MI
 

 
GOAL: Achieve targeted LDL-C reduction

For patients like Tom, PRALUENT provides additional LDL-C lowering on top of a maximally tolerated statin dose

83% of patients in the COMBO I Study achieved LDL-C goal (<70 mg/dL) at week 8 and did not require up-titration at week 121

Only 17% of patients needed to be up-titrated at week 12 from 75 mg to 150 mg1

  • At week 12: 45% LDL-C reduction with PRALUENT 75 mg vs +1% with placebo
  • ASCVD population: Overall, 84% had clinical ASCVD

Reference:
1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.

PRALUENT in hypercholesterolemia patients with PAD
 

 

Hypercholesterolemia with PAD (example of clinical ASCVD)

Medical History

  • Uncontrolled hypercholesterolemia
  • Peripheral artery disease (PAD) of atherosclerotic origin diagnosed 2 years ago
  • Hypertension
  • Prior smoker (30 pack years)

Current Treatment Regimen

  • Rosuvastatin 40 mg/day (maximally tolerated dose)
  • Metoprolol XL 200 mg/day
  • Lisinopril 20 mg/day
  • Cilostazol 100 mg/twice per day
Lipid Profile for hypercholesterolemia patients with PAD
 

 
GOAL: Achieve targeted LDL-C reduction

For patients like Mike, PRALUENT provides additional LDL-C lowering on top of a maximally tolerated statin dose

83% of patients in the COMBO I Study achieved LDL-C goal (<70 mg/dL) at week 8 and did not require up-titration at week 121

Only 17% of patients needed to be up-titrated at week 12 from 75 mg to 150 mg1

  • At week 12: 45% LDL-C reduction with PRALUENT 75 mg vs +1% with placebo
  • ASCVD population: Overall, 84% had clinical ASCVD

Reference:
1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.

PRALUENT in patients with heterozygous familial hypercholesterolemia (HeFH) and poorly controlled LDL-C.
 

 

Heterozygous familial hypercholesterolemia (HeFH) and poorly controlled LDL-C

Medical History

  • HeFH diagnosed at age 18
  • Grandfather died of STEMI at age 52
  • Father had acute coronary syndrome at age 48

Current Treatment Regimen

  • Rosuvastatin 40 mg/day (maximally tolerated dose)
  • Ezetimibe 10 mg/day
Lipid Profile for heterozygous familial hypercholesterolemia (HeFH) and poorly controlled LDL-C
 

 
GOAL: Achieve targeted LDL-C reduction

For patients like Michelle with HeFH, PRALUENT provides powerful LDL-C reduction on top of a maximally tolerated statin

47% LDL-C reduction achieved with PRALUENT 75 mg (up-titration regimen) + statin versus 7% increase with placebo + statin at 24 weeks1

  • At week 12: 66% of patients achieved LDL-C goal based on CV risk2†
  • At week 12: 43% LDL-C reduction with PRALUENT 75 mg vs +5% with placebo1
  • ASCVD population: Overall, 45% of these patients with HeFH also had clinical ASCVD1

HeFH diagnosis by genotyping or by clinical criteria1

  • Clinical criteria: “Definite FH” using either the Simon Broome or WHO/Dutch Lipid Network criteria

References:
1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.
2. Data on file, Sanofi/Regeneron.

Download Resources